Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration

Table 1 Studies included

Sample	Follow-up1	Response	Adverse Events			Ref.
			Infection	Explant	Reoperation
61	13		0	1	2	[60]
16			0	0	3	[61]
85	24		0	3	13	[45]
39	12		2	2	2	[62]
60	47	17	2	9	15	[18]
101	60	26	2	20	20	[14]
50	55.5		2	6	11	[63]
42			0	2	5	[64]
23	114		2	3	5	[65]
101	62		1	10	39	[66]
37	17	27	0	0	3	[50]
41	51		0	0	6	[67]
34	24	83	1	2	4	[19]
37	6		3	5	5	[68]
58	74	37	0	6	15	[49]
12	117		0	3	14	[69]
29	34		0	0	0	[70]
7	32		1	1	2	[71]
53	12		0	0	0	[72]
10			0	0	1	[73]
29	35		2	2	8	[74]
37	13		2	4	10	[75]
14	6		0	0	0	[76]
87	48.5		4	12	36	[77]
40			3	3	7	[78]
15	6	10	0	0	0	[47]
85	12	31	0	1	1	[54]
145	12	137	5	6	15	[6]
29			0	1	1	[79]
27	10.7		3	1	4	[80]
9	12		0	0	1	[81]
120	60	90	12	30	72	[8]
57	63		2	6	12	[82]
8			0	0	1	[83]
18	17		2	3	4	[84]
50	74		4	11	24	[85]
11	14	6	0	1	1	[51]
55	37		1	1	11	[16]
23	38		0	0	4	[15]
32	33		3	7	10	[17]
53	12		0	0	0	[7]
50	12		2	4	10	[86]
10	29.5	10	2	8	8	[53]
33	27	0		5	11	[87]
16	15.5		0	0	0	[88]

¹Follow up in months.